STALE?Report written 3 days ago · at $34.26entry levels may be stale — re-check before acting
VERA
ค่าขนมMID CAP
Vera Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology
$34.26
▲ 1.81%
MCap $3.1B
5 days from FDA PDUFA decision (Jul 7) — Phase 3 hit primary endpoint (46% proteinuria reduction vs baseline, 42% vs placebo). Priority Review + Accelerated Approval pathway.
BusinessIgA Nephropathy biotech · Atacicept BLA under FDA Priority Review · PDUFA Jul 7, 2026 — dual BAFF/APRIL inhibitor, first-in-class mechanism for kidney disease
Thesis
Vera's atacicept has an FDA PDUFA decision due July 7, 2026 — five days from today — for accelerated approval in IgA Nephropathy. Phase 3 ORIGIN data hit its primary endpoint clean (46% proteinuria reduction vs baseline). Goldman Sachs raised its target to $95 (+177%) citing favorable pricing precedent after Travere's Filspari won a broader-than-expected FSGS label in April. This is a true binary event: a clean approval likely re-rates VERA toward the Goldman target or beyond given pipeline optionality (PIONEER trial in membranous nephropathy/FSGS/MCD); a CRL would crash the stock 50%+ same day. Size for the binary, not the trend.
📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม
ค่าขนม SPECULATIVE — 2-3% max given true binary gap risk at the Jul 7 PDUFA. Approval → $61-96 (+80% to +177%), pipeline-optionality Moon → $130 (+280%). CRL crashes to ~$15 (-55%). Size for the loss, not the stop.
88
score / 100 ⓘ
⚡ Catalyst
💊 FDA PDUFA Decision — Atacicept in IgA Nephropathy5 DAYS
FDA target action date for atacicept's Biologics License Application (accelerated approval pathway, Priority Review) in adults with IgA Nephropathy. Phase 3 ORIGIN trial hit its primary endpoint: 46% reduction in proteinuria vs baseline, 42% vs placebo at week 36.
FDA aligned with Vera on an earlier eGFR analysis from the ORIGIN trial. Results expected Q3 2026, supporting a planned supplemental BLA in Q4 2026 for full (non-accelerated) approval — removes the overhang of a future confirmatory-trial requirement.
Atacicept is also being evaluated in anti-PLA2R+ membranous nephropathy and anti-nephrin+ FSGS/MCD. If the BAFF/APRIL mechanism translates beyond IgAN, the addressable market is materially larger than the initial indication alone.
2027+
🎯 Entry Point
Entry 1
$34.26
Current price — only 5 days to PDUFA, limited time to wait for a dipNow (2-3% max, pre-binary)
Entry 2PREFERRED
$29.12–31
Pre-catalyst de-risking dip, if the broader market wobbles into Jul 7If dips this week
Entry 3
$15.42
Post-CRL crash zone — only for high-conviction re-entry on a clear path to resubmissionOnly after a CRL
Pre-PDUFA break — sentiment souring ahead of the event, thesis still technically intact
$27.07
-21%
Hard Stop
CRL / rejection scenario — this is a gap, not a level; the tight stop will not fill on a CRL
$15.42
-55%
Risk / Reward
Entry ($34.26) vs TP2 ($95.93), risk sized to the hard-stop gap ($15.42), not the tight stop
3.3 : 1
⚠ Binary event — size the position for the hard-stop loss, not the tight stop ✅
📅 Estimate Date
FDA PDUFA Decision
Accelerated approval decision for atacicept in IgAN — Priority Review, positive Phase 3
Jul 7, 2026
Approval favored, not guaranteed
ORIGIN eGFR Readout
Supports supplemental BLA for full approval + de-risks post-approval confirmatory requirement
Q3 2026
Positive data expected
📈 Possible Up % — Scenario Spread
Bear
-55%
$15.42
Base
+80%
$61.67
Bull
+180%
$95.93
Moon
+280%
$130.19
← downsideupside →
🏛️ Fed / Macro Risk — LOW
Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution
Rate Outlook
FDA regulatory decisions are event-driven, not rate-sensitive — the Jul 7 PDUFA outcome will move VERA independent of Fed policy.
Inflation
Healthcare/biotech is largely insulated from near-term inflation prints; commercial launch costs (sales force, manufacturing) are the bigger cost variable than macro inflation.
Sector Impact
LOW direct impact from Fed policy, but the current market backdrop (Fed turned hawkish, a hike now priced by October per this week's market-timing read) compresses high-multiple growth/biotech valuations broadly — a clean approval would likely override that, a mixed one would not get the benefit of the doubt.
Summary
Fed risk is LOW for the PDUFA event itself — this is a pure regulatory binary. The broader hawkish-Fed backdrop is a secondary headwind on the multiple, not the catalyst.
🎯 Analyst Targets
Wall Street price targets vs the current price — cross-check our TP levels
Goldman Sachs
Buy$95+177%
current price $34.26
🔍 Similar-Catalyst Comparable Check
Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic
TVTX✅ GoodApr 2026
+34%
in 1 day
Filspari FDA Approval — Expanded FSGS Label
Day-1 move on a broader-than-expected label for a kidney-disease biologic. Direct comp for VERA's IgAN mechanism and the same regulatory pathway archetype.
TVTX✅ GoodApr-May 2026
+46%
in 30 days
Filspari 30-Day Post-Approval Momentum
Approval momentum kept building as commercial launch details emerged — VERA could see a similar extended drift if atacicept clears Jul 7, on top of the day-1 gap.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode
Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.
⚠️
Use this stop-loss set (-21% / -55%) only when trading the earnings spot — not for the core holding (use the -21% / -55% set above). If you are holding long-term, follow the core set.
📈Pre-Catalyst Run-up Pattern
+5-15%2-4 สัปดาห์ก่อน PDUFA
Biotechs with strong Phase 3 data ahead of a PDUFA typically drift up modestly into the decision as institutional positioning builds, then gap violently on the actual readout — the pre-event drift is a small fraction of the post-decision move either direction.
🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +34%
range: +34% to +46%· Apr 2026
Travere Therapeutics (TVTX) Filspari FSGS approval (Apr 13-14, 2026): +33.77% day-1, extending to +46.1% over the following 30 days as commercial details emerged. Closest direct comp — same kidney-disease biologic archetype, adjacent indication.
❌ Catalyst Missavg -50%
range: -40% to -60%· Historical CRL pattern, single-asset biotech
Single-asset biotechs with priced-in approval optimism typically crash 40-60% same day on a CRL, as the market re-rates the entire near-term pipeline to a much lower approval probability.
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio
3% given genuine binary gap risk — even Priority Review + clean Phase 3 data doesn't rule out a CRL on manufacturing/labeling grounds. Size for the -55% hard-stop scenario, not the pre-event tight stop.
🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding